Our website uses cookies to make navigation as functional as possible and to perform statistics on its usage. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here. By continuing to browse this website, you will be accepting our cookies.
26 Mar 2019

A.Menarini Diagnostics and Curetis enter into strategic Pan-European exclusive partnership for the distribution of Curetis' Unyvero

Florence, Italy, March 26th 2019

A.Menarini Diagnostics will be the exclusive distributor for Unyvero Platform and application cartridges in numerous European countries and will deploy its commercial team for the marketing of Unyvero Platform across Europe. By way of this pan-European distribution partnership, the Curetis Unyvero Platform and all CE -IVD marked Unyvero Application Cartridges for rapid detection of pathogens and antimicrobial resistance markers will be exclusively marketed and sold by A.Menarini Diagnostics through its various national country organizations. A.Menarini Diagnostics will dedicate its combined sales, customer service, marketing, scientific affairs and operations support team staff for the commercialization of Curetis’ Unyvero product line.

Effective immediately, Curetis, a developer of next-level molecular diagnostic solutions, will transfer to A.Menarini Diagnostics all of its previous direct selling markets (Germany, France, Benelux, UK, Switzerland). Countries, which were previously covered by individual local distribution partners such as Italy, Spain and Portugal, will also be transferred from Q2-2019 onwards and will be exclusively covered by A.Menarini Diagnostics going forward. As the first Scandinavian market, A.Menarini Diagnostics will also start commercializing the Unyvero Platform in Sweden.

While focusing initially on these markets, the parties are discussing potential future expansions to additional international territories.

“We are excited to partner with Curetis for the commercialization of the Unyvero Platform for rapid detection of pathogens and antimicrobial resistance markers for life-threatening infectious diseases in hospitalized patients across many key European markets. We see this easy-to-use sample-to-answer platform as an important opportunity to improve our molecular diagnostic franchise and further strengthen the commitment of the Menarini Group in the infectious disease area and the fight against life-threatening bacterial diseases following recent significant deals in the anti-infective portfolio,” said Fabio Piazzalunga, General Manager of A. Menarini Diagnostics.

“Entering into this strategic commercial distribution partnership for our flagship Unyvero A50 Platform and all CE-marked cartridges forms a key element of our new corporate strategy that we have outlined in December 2018,” stated Oliver Schacht, CEO of Curetis N.V. “With A.Menarini Diagnostics as our partner we will see more commercial resources being deployed behind Unyvero than would have been possible with Curetis ́ own resources in many countries,” he added.

The partnership, effective immediately, will be launched at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), the key event for clinical microbiology in Europe, which will take place in Amsterdam, The Netherlands, from April 13- 19, 2019.

The parties are also exploring several ways to further expand their collaboration in the future. To this end, they have entered a 90-day period of exclusive negotiations in the field of oncology in certain key territories (such as Europe, Middle East and Africa) for a license to Curetis’ Unyvero A30 RQ Platform, which is currently in development.

About Curetis

Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.

Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in Europe, the Middle East, Asia and the U.S.

Curetis’ wholly owned subsidiary Ares Genetics GmbH is developing next-generation solutions for infectious disease diagnostics and therapeutics. The ARES Technology Platform combines the presumably most comprehensive database worldwide on the genetics of antimicrobial resistances, ARESdb, with advanced bioinformatics and artificial intelligence.

For further information, please visit www.curetis.com and www.ares-genetics.com.






Our Values

10 core values have influenced the progress of our group.